Medicus Pharma (MDCXW) EBT (2024 - 2025)
Medicus Pharma (MDCXW) reported EBT of -$7.8 million for Q4 2025, down 117.28% on a YoY basis from $45.1 million in Q4 2024, and down 51937233.33% quarter-over-quarter from -$15.0 in Q3 2025.
Medicus Pharma (MDCXW) EBT (2024 - 2025) Analysis & Trends
Medicus Pharma has reported EBT for 2 years, with the latest figure at -$7.8 million in Q4 2025.
- For the quarter ending Q4 2025, EBT fell 117.28% year-over-year to -$7.8 million; the trailing twelve-month figure through Dec 2025 stood at -$18.9 million (down 69.12% YoY), and the FY2025 full-year result was -$34.4 million, down 208.0% from the prior year.
- EBT for Q4 2025 stood at -$7.8 million, down from -$15.0 in the prior quarter.
- The five-year high for EBT was -$15.0 in Q3 2025, with the low at -$7.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.89 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 8.85 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 5.99 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.04 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -3.50 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 2.08 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 2.58 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 3.17 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 3.24 Bn |
| 10 | Medicus Pharma | - | - | - | -7.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -7.79 Mn |
| Sep 30, 2025 | -15.00 |
| Jun 30, 2025 | -6.02 Mn |
| Mar 31, 2025 | -5.10 Mn |
| Dec 31, 2024 | -3.59 Mn |
| Sep 30, 2024 | -2.33 Mn |
| Jun 30, 2024 | -3.55 Mn |
| Mar 31, 2024 | -1.71 Mn |